For the first time, the FDA has approved a drug—KEYTRUDA—for cancer-based disease genetics rather than the site of a tumor. KEYTRUDA now can be used for colon, pancreatic, stomach, ovarian and other cancers if genetic testing reveals defects in so-called mismatch repair. The clinical trials for KEYTRUDA were conducted at the Johns Hopkins Bloomberg-Kimmel Institute. The testimonial letter from Johns Hopkins acknowledges that in 2009, Swim Across America was the first organization to believe in the KEYTRUDA research project and provide grant funding for KEYTRUDA clinical trials. In total, over $2.6 million in proceeds from SAA—Baltimore have funded clinical trials and lifesaving research at Johns Hopkins.
Merck issued a press release quoting Swim Across America for providing grant funding for KEYTRUDA clinical trials that helped lead to FDA approval:
“Swim Across America’s mission is to help advance cancer research,” said Rob Butcher, CEO of Swim Across America. “We are honored that our organization supported some of the initial research conducted by Dr. Diaz and team, which has now contributed to the approval of KEYTRUDA for this new indication.”
As a Swim Across America supporter, it’s important you know the impact of our cause. Testimonials from our beneficiaries are published and we encourage you share them with your supporters.